Skip to main content

Timothy J. LaBua

Principal 

Tim is highly adept at counseling emerging growth life science companies in connection with a variety of financing and strategic partnership challenges, as well as merger and acquisition transactions.

He also has extensive experience representing publicly-traded companies and helping business development teams navigate the complexities of early-stage strategic investments and purchase options.

More about Timothy

Associate Attorney

Skadden, Arps, Slate, Meagher & Flom LLP

Associate Attorney

Wilmer Cutler Pickering Hale & Dorr LLP
  • Investment & Operations Counsel at prominent value-focused hedge fund

  • 5AM Ventures and MPM Capital in their purchase of preferred equity in Entrada Therapeutics, Inc.
  • FOG Pharmaceuticals, Inc. in its Series C Financing
  • GV in its purchase of preferred equity in Hyperfine Research, Inc.
  • PIC Therapeutics, Inc. in its Series Seed Financing
  • 5AM Ventures in its purchase of preferred equity in Scientist.com
  • Kanyos Bio, Inc. in its acquisition by Anokion SA
  • Massachusetts Eye and Ear in its subscription for equity in Affinia Therapeutics, Inc.
  • 6Dimensions Capital in its purchase of preferred equity in Halda Therapeutics, Inc.
  • Siamab Therapeutics, Inc. in its acquisition by a publicly listed acquiror
  • HotSpot Therapeutics, Inc. in its acquisition of Macroceutics, Inc.
  • 5AM Ventures in its purchase of preferred equity in VOR Biopharma
  • Kantum Pharma, Inc. in its convertible debt offering
  • Tides Medical LLC in its initial equity financing
  • 6Dimensions Capital in its purchase of preferred equity in HiberCell
  • 5AM Ventures in its purchase of preferred equity in Nido Biosciences
  • GV in its purchase of preferred equity in Endcadia, Inc.
  • Apic Bio, Inc. in its Series A Financing
  • XyloCor Therapeutics, Inc. in its Series A Financing
  • Venn Biosciences Corporation in its Series A Financing
  • Guardian Therapeutics, LLC in its acquisition of Band Therapeutics, LLC
  • Kantum Diagnostics, Inc. in its convertible debt financing
  • Synedgen, Inc. in its out-license of IP and sale of assets to Synspira, LLC
  • Synspira, LLC in its equity/debt financing and research funding from The Cystic Fibrosis Foundation Trust
  • Profit Tools, Inc. in its sale of certain assets to Valsoft Corporation
  • FOG Pharmaceuticals, Inc. in its Series B Financing
  • LifeMine Therapeutics, Inc. in its Series A Financing
  • Renoviso, Inc. in its Series A-1 Financing
  • Lundbeckfond Ventures in its sale of certain royalty rights
  • Bio-Pharm, Inc. in its acquisition by Torrent Pharmaceuticals Ltd.
  • Hexcel Corporation in its acquisition of the aerospace and defense business of Oxford Performance Materials, Inc.
  • Alnylam Pharmaceuticals, Inc. in its strategic collaboration with Vir Biotechnology to develop RNAi therapeutics for infectious diseases
  • .406 Ventures, LLC in its purchase of preferred equity in Trilio Data, Inc.
  • .406 Ventures, LLC as selling shareholder in the acquisition of Jisto, Inc. by Trilio Data, Inc.
  • VivoPharm Pty. Ltd. in its acquisition by Cancer Genetics, Inc.
  • GO Therapeutics, Inc. in its Series A-1 Financing
  • Lysosomal Therapeutics, Inc. in its exclusive option arrangement with Allergan plc
  • PTC Therapeutics, Inc. in its Senior Secured Term Loan Facility
  • Hexcel Corporation in its strategic investment in Carbon Conversions, Inc.

Related Content

Previous Page
Next Page

Interested in working with Timothy?

Our team is eager to learn more about your project

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.